Agios, Celgene deal

Agios and Celgene extended by a year to April 2015 a 2010 cancer metabolism deal, triggering a $20 million payment to Agios. Celgene will now have five years of exclusivity, up from four years, during which it can license drug candidates from Agios at the end of Phase I testing. Celgene can further extend the exclusivity period for one additional year for an additional payment. In 2011, the companies extended the exclusivity period by a year to four years from three years (see BioCentury, April 19, 2010 & Oct. 10, 2011). ...